Skip to main content
. 2022 Apr 15;5(4):e227567. doi: 10.1001/jamanetworkopen.2022.7567

Table 1. Baseline Characteristics.

Characteristic Patients, No. (%) P value
All (N = 496) Low NLR (N = 444) High NLR (N = 52)
Gender
Male 411 (82.9) 373 (84.0) 38 (73.1) .05
Female 85 (17.1) 71 (76.0) 14 (26.9)
Smoker
Never 125 (25.2) 117 (26.4) 8 (15.4) .13
Current 96 (19.4) 82 (18.5) 14 (26.9)
Former 275 (55.4) 245 (55.2) 30 (57.7)
Age, y
<65 344 (69.4) 305 (68.7) 39 (75.0) .43
≥65 152 (30.6) 139 (31.3) 13 (25.0)
Year of radiation
2014 or earlier 259 (52.2) 230 (51.8) 29 (55.8) .66
2015 or later 237 (47.8) 214 (48.2) 23 (44.2)
KPS
<90 135 (27.2) 107 (24.1) 28 (53.8) <.001
90-100 357 (72.0) 334 (75.2) 23 (44.2)
Not available 4 (0.8) 3 (0.7) 1 (1.9)
Race
White 432 (87.1) 387 (87.2) 45 (86.5) .83
Othera 64 (12.9) 57 (12.8) 7 (13.5)
Comorbidity
0 77 (15.5) 68 (15.3) 9 (17.3) .01
1 109 (22.0) 97 (21.8) 12 (23.1)
2 81 (16.3) 65 (14.6) 16 (30.8)
3 107 (21.6) 103 (23.2) 4 (7.7)
>3 122 (24.6) 111 (25.0) 11 (21.2)
Site
Oropharynx 276 (55.6) 239 (53.8) 27 (51.9) .51
Larynx 115 (23.2) 100 (22.5) 15 (28.8)
Oral cavity 12 (2.4) 10 (2.3) 2 (3.8)
Other 93 (18.8) 85 (19.1) 8 (15.4)
T staging
1-2 255 (51.4) 241 (54.3) 14 (26.9) <.001
3-4 241 (48.6) 203 (45.7) 38 (73.1)
N staging
0 97 (19.6) 88 (19.8) 9 (17.3) .10
1 52 (10.5) 46 (10.4) 6 (11.5)
2 307 (61.9) 279 (62.8) 28 (53.8)
3 40 (8.1) 31 (7.0) 9 (17.3)
HPV
Negative 92 (18.5) 77 (17.3) 15 (28.8) .04
Positive 239 (48.2) 222 (50.0) 17 (32.7)
Not available 165 (33.3) 145 (32.7) 20 (38.5)
Chemotherapy
Cisplatin 419 (84.5) 381 (85.8) 38 (73.1) .02
Other 77 (15.5) 63 (14.2) 14 (26.9)

Abbreviations: HPV, human papillomavirus; KPS, Karnofsky performance status; NLR, neutrophil-lymphocyte ratio.

a

The other category for race and ethnicity included African American, American Indian or Alaska Native, Asian, Hispanic, and those who were unknown or declined to answer.